Biosimilars can improve patient access and reduce healthcare costs, but understanding basic concepts about this growing drug class can help optimize those benefits, according to Colin C. Edgerton, MD, a rheumatologist with Articularis Healthcare, in Summerville, S.C.
Different lots of biological products, both reference products and their biosimilars, consist of millions of versions of the same protein, Dr. Edgerton told attendees of the IgNS 2024 National Conference, in